Do you want to expand the coverage for most chronic diseases, or for the most common ones? The coverage for more specific and less prevalent diseases is more expensive. The fewer the patients, the higher the cost of the research and drug. It's a matter of math. Canada has a population of 36 million. The United States has a population of over 300 million. When research is conducted, the market is completely different. How do you deal with this aspect? What's your solution?
What do you think, Mr. MacLeod?